VBI Total Other Income Expense Net vs Cost Of Revenue Analysis

VBIV Stock

USD 0.63 0.02 3.08%

VBI Vaccines financial indicator trend analysis is much more than just breaking down VBI Vaccines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VBI Vaccines is a good investment. Please check the relationship between VBI Vaccines Total Other Income Expense Net and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.

Total Other Income Expense Net vs Cost Of Revenue

Total Other Income Expense Net vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VBI Vaccines Total Other Income Expense Net account and Cost Of Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between VBI Vaccines' Total Other Income Expense Net and Cost Of Revenue is -0.31. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of VBI Vaccines, assuming nothing else is changed. The correlation between historical values of VBI Vaccines' Total Other Income Expense Net and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of VBI Vaccines are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Total Other Income Expense Net i.e., VBI Vaccines' Total Other Income Expense Net and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.31

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Other Income Expense Net

Cost Of Revenue

Cost of Revenue is found on VBI Vaccines income statement and represents the costs associated with goods and services VBI Vaccines provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.76) in 2024.

	2023	2024 (projected)
Non Recurring	5.7M	5.0M
Reconciled Depreciation	2.0M	1.6M

Non Recurring Reconciled Depreciation

VBI Vaccines fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Total Current Liabilities	Accounts Payable	Net Receivables	Non Current Liabilities Total	Short Term Investments	Other Assets	Short Long Term Debt Total	Inventory	Other Current Liab	Short Term Debt	Common Stock Total Equity
Total Assets		0.89	0.49	-0.66	-0.06	0.72	0.83	0.49	0.74	-0.06	0.09	0.45	0.23	0.5	0.72	-0.11	0.12	-0.14	0.55	0.27	0.46	0.14	-0.15	0.39	-0.42	0.55
Total Stockholder Equity	0.89		0.59	-0.73	0.36	0.55	0.79	0.25	0.62	-0.42	-0.28	0.32	-0.24	0.6	0.56	-0.49	-0.28	-0.35	0.27	0.36	0.3	-0.21	-0.51	0.06	-0.63	0.17
Property Plant And Equipment Net	0.49	0.59		0.04	0.4	-0.19	0.84	-0.16	-0.14	-0.34	-0.3	0.54	-0.19	0.97	-0.18	-0.36	-0.35	0.18	0.19	-0.04	-0.44	0.16	-0.28	-0.41	-0.25	-0.08
Net Debt	-0.66	-0.73	0.04		-0.21	-0.81	-0.28	-0.38	-0.84	0.32	0.19	0.0	0.16	0.05	-0.8	0.4	0.15	0.62	-0.29	-0.44	-0.72	0.49	0.53	-0.42	0.68	-0.19
Retained Earnings	-0.06	0.36	0.4	-0.21		-0.33	0.21	-0.51	-0.29	-0.95	-0.73	-0.09	-0.89	0.32	-0.36	-0.94	-0.82	-0.54	-0.21	0.08	-0.29	-0.73	-0.91	-0.61	-0.67	-0.81
Cash	0.72	0.55	-0.19	-0.81	-0.33		0.22	0.73	0.97	0.19	0.27	-0.02	0.33	-0.14	0.97	0.12	0.33	-0.34	0.41	0.23	0.78	0.03	0.02	0.75	-0.32	0.61
Non Current Assets Total	0.83	0.79	0.84	-0.28	0.21	0.22		0.1	0.23	-0.28	-0.1	0.59	0.07	0.8	0.2	-0.24	-0.1	0.04	0.45	0.1	-0.03	0.19	-0.26	-0.02	-0.35	0.23
Non Currrent Assets Other	0.49	0.25	-0.16	-0.38	-0.51	0.73	0.1		0.69	0.37	0.66	-0.04	0.47	-0.04	0.73	0.25	0.56	-0.24	0.5	0.05	0.57	0.37	0.32	0.82	-0.18	0.7
Cash And Short Term Investments	0.74	0.62	-0.14	-0.84	-0.29	0.97	0.23	0.69		0.18	0.21	0.05	0.25	-0.07	0.99	0.06	0.27	-0.32	0.35	0.36	0.8	-0.04	-0.01	0.66	-0.34	0.6
Common Stock Shares Outstanding	-0.06	-0.42	-0.34	0.32	-0.95	0.19	-0.28	0.37	0.18		0.58	0.06	0.79	-0.27	0.25	0.93	0.66	0.65	0.07	-0.13	0.13	0.7	0.93	0.42	0.79	0.7
Other Current Assets	0.09	-0.28	-0.3	0.19	-0.73	0.27	-0.1	0.66	0.21	0.58		0.06	0.76	-0.23	0.3	0.55	0.92	0.15	0.56	-0.28	0.39	0.66	0.71	0.63	0.21	0.61
Other Stockholder Equity	0.45	0.32	0.54	0.0	-0.09	-0.02	0.59	-0.04	0.05	0.06	0.06		0.28	0.54	0.06	0.13	0.1	0.53	0.26	0.13	-0.13	0.4	0.04	-0.02	0.07	0.26
Total Liab	0.23	-0.24	-0.19	0.16	-0.89	0.33	0.07	0.47	0.25	0.79	0.76	0.28		-0.19	0.32	0.83	0.85	0.49	0.55	-0.21	0.3	0.76	0.78	0.65	0.49	0.77
Property Plant And Equipment Gross	0.5	0.6	0.97	0.05	0.32	-0.14	0.8	-0.04	-0.07	-0.27	-0.23	0.54	-0.19		-0.11	-0.3	-0.3	0.21	0.1	0.0	-0.44	0.25	-0.19	-0.37	-0.21	-0.01
Total Current Assets	0.72	0.56	-0.18	-0.8	-0.36	0.97	0.2	0.73	0.99	0.25	0.3	0.06	0.32	-0.11		0.12	0.35	-0.28	0.39	0.33	0.83	0.02	0.06	0.71	-0.29	0.67
Total Current Liabilities	-0.11	-0.49	-0.36	0.4	-0.94	0.12	-0.24	0.25	0.06	0.93	0.55	0.13	0.83	-0.3	0.12		0.69	0.72	0.0	-0.13	0.04	0.75	0.91	0.41	0.84	0.64
Accounts Payable	0.12	-0.28	-0.35	0.15	-0.82	0.33	-0.1	0.56	0.27	0.66	0.92	0.1	0.85	-0.3	0.35	0.69		0.24	0.51	-0.1	0.43	0.66	0.74	0.69	0.3	0.68
Net Receivables	-0.14	-0.35	0.18	0.62	-0.54	-0.34	0.04	-0.24	-0.32	0.65	0.15	0.53	0.49	0.21	-0.28	0.72	0.24		-0.2	-0.18	-0.47	0.7	0.67	-0.2	0.84	0.3
Non Current Liabilities Total	0.55	0.27	0.19	-0.29	-0.21	0.41	0.45	0.5	0.35	0.07	0.56	0.26	0.55	0.1	0.39	0.0	0.51	-0.2		-0.17	0.47	0.26	0.08	0.55	-0.35	0.44
Short Term Investments	0.27	0.36	-0.04	-0.44	0.08	0.23	0.1	0.05	0.36	-0.13	-0.28	0.13	-0.21	0.0	0.33	-0.13	-0.1	-0.18	-0.17		0.34	-0.4	-0.31	0.15	-0.22	0.12
Other Assets	0.46	0.3	-0.44	-0.72	-0.29	0.78	-0.03	0.57	0.8	0.13	0.39	-0.13	0.3	-0.44	0.83	0.04	0.43	-0.47	0.47	0.34		-0.21	0.0	0.72	-0.35	0.47
Short Long Term Debt Total	0.14	-0.21	0.16	0.49	-0.73	0.03	0.19	0.37	-0.04	0.7	0.66	0.4	0.76	0.25	0.02	0.75	0.66	0.7	0.26	-0.4	-0.21		0.82	0.29	0.59	0.59
Inventory	-0.15	-0.51	-0.28	0.53	-0.91	0.02	-0.26	0.32	-0.01	0.93	0.71	0.04	0.78	-0.19	0.06	0.91	0.74	0.67	0.08	-0.31	0.0	0.82		0.31	0.79	0.61
Other Current Liab	0.39	0.06	-0.41	-0.42	-0.61	0.75	-0.02	0.82	0.66	0.42	0.63	-0.02	0.65	-0.37	0.71	0.41	0.69	-0.2	0.55	0.15	0.72	0.29	0.31		-0.08	0.7
Short Term Debt	-0.42	-0.63	-0.25	0.68	-0.67	-0.32	-0.35	-0.18	-0.34	0.79	0.21	0.07	0.49	-0.21	-0.29	0.84	0.3	0.84	-0.35	-0.22	-0.35	0.59	0.79	-0.08		0.26
Common Stock Total Equity	0.55	0.17	-0.08	-0.19	-0.81	0.61	0.23	0.7	0.6	0.7	0.61	0.26	0.77	-0.01	0.67	0.64	0.68	0.3	0.44	0.12	0.47	0.59	0.61	0.7	0.26

Click cells to compare fundamentals

VBI Vaccines Account Relationship Matchups

VBI Vaccines fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	122.2M	209.4M	210.3M	155.1M	87.0M	73.5M
Total Stockholder Equity	88.3M	171.7M	143.9M	64.2M	7.5M	7.2M
Property Plant And Equipment Net	10.2M	10.7M	11.0M	12.3M	11.9M	21.9M
Net Debt	(29.4M)	(92.9M)	(89.9M)	(10.4M)	29.4M	30.8M
Retained Earnings	(262.4M)	(308.6M)	(378.4M)	(489.6M)	(582.4M)	(553.3M)
Cash	44.2M	93.8M	121.7M	62.6M	23.7M	28.9M
Non Current Assets Total	75.2M	77.3M	80.0M	77.4M	50.7M	42.9M
Non Currrent Assets Other	2.1M	2.2M	4.6M	4.7M	1.2M	992.6K
Cash And Short Term Investments	44.2M	119.1M	121.7M	62.6M	23.7M	31.5M
Common Stock Shares Outstanding	4.0M	7.3M	8.5M	8.6M	15.6M	16.4M
Liabilities And Stockholders Equity	122.2M	209.4M	210.3M	155.1M	87.0M	73.5M
Other Current Assets	450K	1.3M	2.2M	8.4M	2.8M	2.9M
Other Stockholder Equity	66.4M	75.5M	81.6M	90.0M	107.4M	112.8M
Total Liab	33.9M	37.7M	66.4M	90.9M	79.4M	83.4M
Property Plant And Equipment Gross	11.7M	12.3M	19.3M	23.6M	22.3M	27.7M
Total Current Assets	47.0M	132.0M	130.3M	77.7M	36.2M	33.0M
Total Current Liabilities	29.8M	17.3M	32.6M	36.9M	75.7M	79.5M
Accounts Payable	1.1M	3.7M	4.3M	13.0M	6.4M	6.8M
Net Receivables	201K	77K	8K	94K	1.3M	1.3M
Non Current Liabilities Total	4.2M	20.3M	33.8M	54.0M	3.7M	3.5M
Accumulated Other Comprehensive Income	(752K)	1.3M	(1.6M)	21.4M	28.3M	29.7M
Other Assets	620K	2.2M	1.3M	1.4M	1.0	0.95
Short Long Term Debt Total	14.8M	944K	31.8M	52.2M	53.0M	55.7M
Inventory	1.1M	2.2M	2.6M	6.6M	8.5M	8.9M
Other Current Liab	12.9M	12.4M	26.9M	22.6M	6.7M	5.7M
Short Term Debt	14.8M	944K	839K	972K	51.7M	54.3M
Common Stock Total Equity	285.0M	403.5M	442.2M	442.3M	508.7M	260.5M
Common Stock	285.0M	403.5M	442.2M	442.3M	454.2M	247.1M
Net Tangible Assets	25.3M	107.3M	79.5M	3.7M	4.2M	4.0M
Current Deferred Revenue	882K	255K	526K	409K	10.9M	11.4M
Intangible Assets	60.8M	62.2M	62.1M	58.3M	36.5M	47.5M
Property Plant Equipment	11.7M	10.7M	11.0M	12.3M	14.1M	14.8M
Other Liab	3.4M	3.4M	2.9M	2.7M	3.1M	2.7M
Short Long Term Debt	1.6M	1.1M	14.8M	50.8M	58.4M	61.3M
Capital Surpluse	66.4M	75.5M	81.6M	90.0M	103.5M	75.2M
Good Will	8.3M	2.2M	2.3M	2.1M	1.1M	1.1M
Retained Earnings Total Equity	(262.4M)	(308.6M)	(378.4M)	(489.6M)	(440.6M)	(418.6M)

When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:

How To Invest In VBI

Details

Is VBI Stock a good investment?

Details

What is VBI Vaccines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for VBI Stock analysis

When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.

	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Stocks Directory Find actively traded stocks across global markets
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Bonds Directory Find actively traded corporate debentures issued by US companies
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.03)

Revenue Per Share

0.558

Quarterly Revenue Growth

1.911

Return On Assets

(0.29)

Return On Equity

(2.59)

The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

VBI Total Other Income Expense Net vs Cost Of Revenue Analysis

Total Other Income Expense Net vs Cost Of Revenue

Total Other Income Expense Net vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Total Other Income Expense Net

Cost Of Revenue

VBI Vaccines fundamental ratios Correlations

VBI Vaccines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

VBI Vaccines fundamental ratios Accounts

Complementary Tools for VBI Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.97	Cash
Total Current Assets	+ 0.97	Cash
Total Current Liabilities	+ 0.93	Common Stock Shares Outstanding
Inventory	+ 0.93	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.95	Retained Earnings
Total Current Liabilities	- 0.94	Retained Earnings
Inventory	- 0.91	Retained Earnings
Total Liab	- 0.89	Retained Earnings
Cash And Short Term Investments	- 0.84	Net Debt
Accounts Payable	- 0.82	Retained Earnings